CN Patent

CN113372285B — 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用

Assigned to Affiliated Hospital of Southwest Medical University · Expires 2024-06-18 · 2y expired

What this patent protects

本发明公开了前列腺特异性膜抗原抑制剂、其放射性核素标记物及制备方法和应用，属于生物医药技术领域。本发明的前列腺特异性膜抗原抑制剂的化学结构如式Ⅰ所示，其放射性核素标记物的化学结构如式Ⅱ所示，用于在制备前列腺癌诊断试剂/药物、或/和治疗药物。本发明化合物结构新颖，物理化学性质稳定，能用于制备前列腺癌诊断及治疗药物中用于前列腺癌的诊断、分期、疗效评估和治疗领域。

USPTO Abstract

本发明公开了前列腺特异性膜抗原抑制剂、其放射性核素标记物及制备方法和应用，属于生物医药技术领域。本发明的前列腺特异性膜抗原抑制剂的化学结构如式Ⅰ所示，其放射性核素标记物的化学结构如式Ⅱ所示，用于在制备前列腺癌诊断试剂/药物、或/和治疗药物。本发明化合物结构新颖，物理化学性质稳定，能用于制备前列腺癌诊断及治疗药物中用于前列腺癌的诊断、分期、疗效评估和治疗领域。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN113372285B
Jurisdiction: CN
Classification: —
Expires: 2024-06-18
Drug substance claim: No
Drug product claim: No
Assignee: Affiliated Hospital of Southwest Medical University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.